Published • loading... • Updated
Phase III Success Pushes Kodiak’s Eye Treatment Towards Approval
Kodiak said 54% of Zenkuda patients reached a six-month dosing interval, while both drugs matched aflibercept on vision gains.
- On Monday, Kodiak Sciences announced positive Phase III results from the DAYBREAK study, evaluating Zenkuda and tabirafusp-ted in 690 patients with wet age-related macular degeneration.
- Current Wet AMD treatments like Eyelea and Vabysmo require injections every four to eight weeks; Zenkuda is designed to remedy this burden by extending the interval between treatments.
- Data from DAYBREAK shows 54% of patients achieved a 6-month dosing interval by year one, with Zenkuda efficacy matching Eyelea when using optical coherence tomography guidance for retreatment decisions.
- Chief medical officer J. Pablo Velazquez-Martin said the study demonstrated "rapid disease control in wet AMD and the potential for six-month durability," validating Kodiak's design strategy for Zenkuda.
- Kodiak plans to submit Zenkuda for FDA approval across three indications—wet AMD, diabetic retinopathy, and macular edema—in the coming months based on five positive Phase III trials.
Insights by Ground AI
24 Articles
24 Articles
The Billings Gazette+12 Reposted by 12 other sources
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left2Leaning Right1Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
13%
C 81%
Factuality
To view factuality data please Upgrade to Premium
